HLA typing, analysis methods, and clinical applications;Typage HLA, méthodes d'analyses et applications cliniques

Presse Medicale

Volumn 34, Issue 15, 2005, Pages 1101-1108

  Moalic, Virginie ^a   Ferec, C ^a  

^a CHU MORVAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELISM; ANTIGEN PRESENTATION; DISEASE ASSOCIATION; GENETIC VARIABILITY; HLA TYPING; IMMUNE RESPONSE; IMMUNE SYSTEM; NOMENCLATURE; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; REVIEW; SEROLOGY; STEM CELL TRANSPLANTATION;

EID: 24944473424     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(05)84126-0     Document Type: Short Survey

References (58)

1. Dausset J. Iso-leucoantibodies. Acta Haematol 1958; 20: 156-66.
2. The MHC Consortium. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature 1999; 401: 921-3.
3. Rhodes DA, Trowsdale J. Genetics and molecular genetics of the MHC. Rev Immunogenet 1999; 1: 21-31.
4. Campbell DR, Trowsdale J. Map of the human MHC. Immunol Today 1993; 14: 349-52.
5. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329: 506-12.
6. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996; 384: 134-41.
7. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993; 364: 33-9.
8. Williams TM. Human leukocyte antigen gene polymorphism and the histocompatibility laboratory. J Mol Diagn 2001; 3: 98-104.
9. Monaco JJ. Pathways for the processing and presentation of antigens to T cells. J Leukoc Biol 1995; 57: 543-7.
10. Cresswell P, Howard JC. Antigen recognition. Curr Opin Immunol 1997; 9: 71-4.
11. Bignon JD. Système HLA. Encycl Med Chir, Hématologie, 13-000-M-53, 2000, 16p.
12. Erlich HA, Opelz G, Hansen J. HLA DNA typing and transplantation. Immunity 2001; 14: 347-56.
13. Klein J, Sato A. The HLA system. N Engl J Med 2000; 343: 702-9.
14. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA et al. Nomenclature for factors of the HLA system, 2002. Tissue Antigens 2002; 60: 407-64.
15. Dupont B. Nomenclature for factors of the HLA system, 1987. Decisions of the Nomenclature Committee on Leukocyte Antigens, which met in New York on November 21-23, 1987. Hum Immunol 1989; 26: 3-14.
16. Terasaki PJ, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964; 204: 998-1000.
17. Saiki RK, Walsh PS, Levenson CH, Erlich HA. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci USA 1989; 86: 6230-4.
18. Gerlach JA. Human lymphocyte antigen molecular typing: how to identify the 1250 alleles out there. Arch Pathol Lab Med 2002; 126: 281-4.
19. Suberbielle-Boissel C, Chapuis E, Charron D, Raffoux C. Comparative study of two methods of HLA-DR typing: serology and PCR/Dot Blot Reverse. Transplant Proc 1997; 29: 2335-6.
20. Buyse I, Decorte R, Baens M, Cuppens H, Semana G, Emonds MP et al. Rapid DNA typing of class II HLA antigens using the polymerase chain reaction and reverse dot blot hybridization. Tissue Antigens 1993; 41: 1-14.
21. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 HOUR: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-35.
22. Fulton RJ, McDade RL, Smith PL, Kienker LJ, Kettman JR Jr. Advanced multiplexed analysis with the FlowMetrix system. Clin Chem 1997; 43: 1749-56.
23. Joos TO, Stoll D, Templin MF. Miniaturised multiplexed immunoassays. Curr Opin Chem Biol 2001; 6: 76-80.
24. Adams SD, Barracchini KC, Simonis TB, Stroncek D, Marincola FM. High throughput HLA sequence-based typing (SBT) utilizing the ABI Prism 3700 DNA Analyzer. Tumori 2001; 87: S40-3.
25. Delpech M. Les puces à ADN. Ann Biol Clin 2000; 58: 29-38.
26. Guo Z, Hood L, Petersdorf EW. Oligonucleotide arrays for high throughput resolution HLA typing. Rev Immunogenet 1999; 1: 220-30.
27. Opelz G, Wujciak T, Dohler B, Scherer S, Mytilineos J. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet 1999; 1: 33442.
28. Roberts JP, Wolfe RA, Bragg-Gresham JL, Rush SH, Wynn JJ, Distant DA et al. Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. N Engl J Med 2004; 350: 545-51.
29. Raffoux C, Bignon JD. Quel cross-match avant transplantation en 1997? Presse Med 1997; 26: 867-71.
30. Etablissement Français des greffes. Rapport d'activité de prélèvements et de greffes 2003. Rennes.
31. Petersdorf EW, Gooley TA, Anasetti C, Martin PJ, Smith AG, Mickelson EM et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998; 92: 3515-20.
32. Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998; 339: 1177-85.
33. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104: 1923-30.
34. Fajardy I, Rousseaux J, Danze PM. Le système HLA: une aide à la clinique? Ann Biol Clin 1997; 55: 93-101.
35. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1973; 288: 704-6.
36. Khan MA, Ball EJ. Genetic aspects of ankylosing spondylitis. Best Pract Res Clin Rheumatol 2002; 16: 675-90.
37. Olivieri I, van Tubergen A, Salvarani C, van der Linden S. Seronegative spondyloarthritides. Best Pract Res Clin Rheumatol 2002; 16: 723-39.
38. Toubert A. From the HLA-B27 molecule to spondylarthropathy. Rev Med Interne 1999; 20 Suppl 1: 295-305
39. Tieng V, Charron D, Toubert A. Sous-types de la molécule HLA-B27 et spondylarthropathies. Pathol Biol 1998; 46: 737-40.
40. Brown M, Wordsworth P. Predisposing factors to spondylarthropathies. Curr Opin Rheumatol 1997; 9: 308-14.
41. Toussirot E, Wending D. Polyarthrite Rhumatoïde: ses liens avec les molecules HLA DR. Presse Med 1995; 24: 855-8.
42. Combe B. Evolution, surveillance et pronostic de la polyarthrite rhumatoide. Rev Prat 1997; 47: 2017-21.
43. Benazet JF, Reviron D, Mercier P, Roux H, Roudier J. HLA-DRB1 alleles associated with rheumatoid arthritis in southern France. Absence of extraarticular disease despite expression of the shared epitope. J Rheumatol 1995; 22: 607-10.
44. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-13.
45. Morel J, Miossec P, Combe B. Immunopathologie de la polyarthrite rhumatoïde. EMC-Rhumatologie Orthopédie 2004; 1: 218-30.
46. Reviron D, Perdriger A, Toussirot E, Wendung D, Balandraud N, Guis S et al. Influence of shared epitope-negative HLA-DRB1 alleles on genetic susceptibility to rheumatoid arthritis. Arthritis Rheum 2001; 44: 535-40.
47. Wordsworth P, Pile KD, Buckely JD, Lanchbury JS, Oilier B, Lathrop M et al. HLA heterozygosity contributes to susceptibility to rheumatoid arthritis. Am J Hum Genet 1992; 51: 585-91.
48. Saraux A, Guedes C, Allain J, Devauchelle V, Valls I, Baron D et al. Valeur diagnostique du phénotype HLA dans les rhumatismes inflammatoires. Presse Med 1997; 26: 1040-4.
49. Kelly MA, Rayner ML, Mijovic CH, Barnett AH. Molecular aspects of type 1 diabetes. Mol Pathol 2003; 56: 1-10.
50. Caillat-Zucman S, Garchon HJ, Timsit J, Assan R, Boitard C, Djilali-Saiah I et al. Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J Clin Invest 1992; 90: 2242-50.
51. Levin L, Tomer Y. The etiology of autoimmune diabetes and thyroiditis: evidence for common genetic susceptibility. Autoimmun Rev 2003; 2: 377-86.
52. Pociot F, McDermott MF. Genetics of type 1 diabetes mellitus. Genes Immun 2002; 3: 235-49.
53. Mignot E, Tafti M, Dement WC, Grumet FC. Narcolepsy and immunity. Adv Neuroimmunol 1995; 5: 23-37.
54. Lepers S, Couignoux S, Colombel JF, Dubucquoi S. La maladie cœliaque de l'adulte: aspects nouveaux. Rev Med Interne 2004; 25: 22-34.
55. Simon M, Bourel M, Fauchet R, Genetet B. Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. Gut 1976; 17: 332-4.
56. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
57. Hill AV, Elvin J, Willis AC, Aidoo M, Allsopp CE, Gotch FM et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992; 360: 434-9.
58. Malkovsky M. HLA and natural history of HIV infection. Lancet 1996; 348: 142-3.